show all | hide all No of entries

Information on EC 1.1.1.62 - 17beta-estradiol 17-dehydrogenase and Organism(s) Homo sapiens

for references in articles please use BRENDA:EC1.1.1.62
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
IUBMB Comments
The enzyme oxidizes or reduces the hydroxy/keto group on C17 of estrogens and androgens in mammals and regulates the biological potency of these steroids. The mammalian enzyme is bifunctional and also catalyses EC 1.1.1.270, 3beta-hydroxysteroid 3-dehydrogenase . The enzyme also acts on (S)-20-hydroxypregn-4-en-3-one and related compounds, oxidizing the (S)-20-group, but unlike EC 1.1.1.149, 20alpha-hydroxysteroid dehydrogenase, it is Si-specific with respect to NAD(P)+.
Specify your search results
The word/phrase is now marked yellow!
Select one or more organisms in this record:
This record set is specific for:
Homo sapiens
Word Map
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
Synonyms
hsd17b1, 17beta-hsd1, 20 alpha-hydroxysteroid dehydrogenase, hsd17b2, 17betahsd, hsd17b4, 17-hsd, akr1c4, 17beta-hydroxysteroid dehydrogenase type 1, hsd17b12, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
(17beta-HSD) type 1
-
-
(17beta-HSD) type 2
-
-
17-HOR
-
-
-
-
17-HSD
-
-
-
-
17beta HSD1
-
-
17beta,20alpha-hydroxysteroid dehydrogenase
-
-
-
-
17beta-estradiol dehydrogenase
-
-
-
-
17beta-HSD
17beta-HSD I
-
-
17beta-HSD type 1
-
-
17beta-HSD type 12
-
-
17beta-HSD type 2
-
-
17beta-HSD type 5
-
-
17beta-HSD type 7
-
-
17beta-HSD type 8
-
-
17beta-HSD1
17beta-HSD12
-
17beta-HSD14
-
17beta-HSD2
17beta-HSD5
-
-
17beta-HSD7 2
Q5MGS6
-
17beta-hydroxysteroid dehydrogenase
17beta-hydroxysteroid dehydrogenase 1
-
17beta-hydroxysteroid dehydrogenase 2
-
17beta-hydroxysteroid dehydrogenase 4
-
-
17beta-hydroxysteroid dehydrogenase type 1
17beta-hydroxysteroid dehydrogenase type 12
-
-
17beta-hydroxysteroid dehydrogenase type 14
-
17beta-hydroxysteroid dehydrogenase type 2
17beta-hydroxysteroid dehydrogenase type 4
-
-
17beta-hydroxysteroid dehydrogenase type 5
-
-
17beta-hydroxysteroid dehydrogenase type 6
-
17beta-hydroxysteroid dehydrogenase type 7
-
-
17beta-hydroxysteroid dehydrogenase type 8
-
-
17beta-hydroxysteroid dehydrogenase type I
-
-
17beta-hydroxysteroid dehydrogenase types 1
-
-
17beta-hydroxysteroid dehydrogenases type 1
-
-
17betaHSD1
17betaHSD14
-
17betaHSD6
-
17HSD1
-
-
20 alpha-hydroxysteroid dehydrogenase
-
-
-
-
20-alpha-HSD
-
-
-
-
20alpha-hydroxysteroid dehydrogenase
7beta-HSD type 1
-
AKR1C1
-
-
AKR1C2
-
-
AKR1C4
-
-
aldo-keto reductase 1B15
-
dehydrogenase, estradiol 17beta-
-
-
-
-
E2DH
-
-
-
-
EDH
-
-
-
-
estradiol 17beta-dehydrogenase
-
-
-
-
estradiol dehydrogenase
-
-
-
-
estrogen 17-oxidoreductase
-
-
-
-
estrogenic 17beta-hydroxysteroid dehydrogenase
-
-
form 2 type 7 17beta-hydroxysteroid dehydrogenase
Q5MGS6
-
HSD17B1
HSD17B2
hydroxysteroid (17-beta) dehydrogenase 1
-
-
Ke6 protein
-
-
-
-
microsomal 17-beta-hydroxysteroid dehydrogenase
-
-
-
-
oestradiol-17beta hydroxysteroid dehydrogenase
-
-
-
-
placental 17-beta-hydroxysteroid dehydrogenase
-
-
-
-
PRAP
-
-
-
-
PRL receptor associated protein
-
-
-
-
testicular 17-beta-hydroxysteroid dehydrogenase
-
-
-
-
type 1 17beta-HSD
-
-
type 1 17beta-hydroxysteroid dehydrogenase
-
-
type 12 17beta-hydroxysteroid dehydrogenase
-
additional information
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
17beta-estradiol + NAD(P)+ = estrone + NAD(P)H + H+
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
17beta-estradiol:NAD(P)+ 17-oxidoreductase
The enzyme oxidizes or reduces the hydroxy/keto group on C17 of estrogens and androgens in mammals and regulates the biological potency of these steroids. The mammalian enzyme is bifunctional and also catalyses EC 1.1.1.270, 3beta-hydroxysteroid 3-dehydrogenase [3]. The enzyme also acts on (S)-20-hydroxypregn-4-en-3-one and related compounds, oxidizing the (S)-20-group, but unlike EC 1.1.1.149, 20alpha-hydroxysteroid dehydrogenase, it is Si-specific with respect to NAD(P)+.
CAS REGISTRY NUMBER
COMMENTARY hide
9028-61-9
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
1,2-dimethyl-6-dehydroestrone + NADH
1,2-dimethyl-6-dehydroestradiol + NAD+
show the reaction diagram
-
-
-
-
?
1,2-dimethylestradiol + NAD+
1,2-dimethylestrone + NADH
show the reaction diagram
-
-
-
-
r
1,2-dimethylestrone + NADH
1,2-dimethylestradiol + NAD+
show the reaction diagram
-
-
-
-
r
1,3-dimethyl-6-dehydroestrone + NADH
1,3-dimethyl-6-dehydroestradiol + NAD+
show the reaction diagram
-
-
-
-
?
1,4-diacetoxy-1,3,5(10)-estratrien-17-one + NADH
17beta-hydroxy-1,4-diacetoxy-1,3,5(10)-estratriene + NAD+
show the reaction diagram
-
-
-
-
?
1,4-dihydroxy-1,3,5(10)-estratrien-17-one + NADH
1,4,17-trihydroxy-1,3,5(10)-estratrien + NAD+
show the reaction diagram
-
-
-
-
?
1-methyl-6-dehydroestradiol + NAD+
1-methyl-6-dehydroestrone + NADH
show the reaction diagram
-
-
-
-
r
1-methyl-6-dehydroestrone + NADH
1-methyl-6-dehydroestradiol + NAD+
show the reaction diagram
-
-
-
-
r
1-methylestradiol + NAD+
1-methylestrone + NADH
show the reaction diagram
-
-
-
-
?
11-ketoequilenin acetate + NADH
17beta-hydroxy-11-ketoequilenin acetate + NAD+
show the reaction diagram
-
-
-
-
?
11alpha-hydroxyestradiol + NAD+
11alpha-hydroxyestrone + NADH
show the reaction diagram
-
-
-
-
?
11beta-hydroxyestradiol + NAD+
11beta-hydroxyestrone + NADH
show the reaction diagram
-
-
-
-
?
16-ketoestrone + NADH
16-ketoestradiol + NAD+
show the reaction diagram
-
-
-
-
?
17beta-estradiol + NAD(P)+
estrone + NAD(P)H + H+
show the reaction diagram
-
-
-
-
r
17beta-estradiol + NAD+
estrone + NADH + H+
show the reaction diagram
17beta-estradiol + NADP+
estrone + NADPH
show the reaction diagram
17beta-estradiol + NADP+
estrone + NADPH + H+
show the reaction diagram
-
-
-
?
18-nor-D-homoestrone 3-methyl ether + NADH
18-nor-D-homoestradiol 3-methyl ether + NAD+
show the reaction diagram
-
-
-
-
?
19-nortestosterone + NAD+
4-estren-3,17-dione + NADH
show the reaction diagram
-
2% of the activity with estradiol-17beta
-
-
?
2,4-dinitroestradiol + NAD+
2,4-dinitroestrone + NADH
show the reaction diagram
-
-
-
-
r
2,4-dinitroestrone + NADH
2,4-dinitroestradiol + NAD+
show the reaction diagram
-
-
-
-
r
2,4-dinitroestrone 3-oxyacetic acid ether + NADH
2,4-dinitroestradiol 3-oxyacetic acid ether + NAD+
show the reaction diagram
-
-
-
-
?
2,5(10)-estradiene-1,4,17-trione + NADH
17beta-hydroxy-2,5(10)-estradiene-1,4-dione + NAD+
show the reaction diagram
-
-
-
-
?
2-aminoestradiol + NAD+
2-aminoestrone + NADH
show the reaction diagram
-
-
-
-
?
2-methoxyestrone + NADH
2-methoxyestradiol + NAD+
show the reaction diagram
-
-
-
-
?
2-methylestradiol + NAD+
2-methylestrone + NADH
show the reaction diagram
-
-
-
-
?
2-nitroestradiol + NAD+
2-nitroestrone + NADH
show the reaction diagram
-
-
-
-
r
2-nitroestrone + NADH
2-nitroestradiol + NAD+
show the reaction diagram
-
-
-
-
r
2-nitroestrone 3-oxyacetic acid ester + NADH + H+
2-nitroestradiol-17beta-3-oxyacetic acid ester + NAD+
show the reaction diagram
-
-
-
-
?
20alpha-hydroxy-4-pregnen-3-one + NADP+
4-pregnen-3,20-dione + NADPH
show the reaction diagram
3-hydroxy-2,5(10)-estradiene-1,4,17-trione + NADH
3,17beta-dihydroxy-2,5(10)-estradiene-1,4-dione + NAD+
show the reaction diagram
-
-
-
-
?
3-methyl-O-estradiol + NAD(P)+
3-methyl-O-estrone + NAD(P)H
show the reaction diagram
-
-
-
-
?
3-O-methyl-17beta-estradiol + NAD+
3-O-methylestrone + NADH
show the reaction diagram
-
-
-
-
?
3beta-hydroxyandrost-5-en-17-one + NADPH
3beta,17beta-dihydroxyandrost-5-ene + NADP+
show the reaction diagram
-
i.e. dehydroepiandrosterone
-
-
?
4-aminoestrone + NADH
4-aminoestradiol + NAD+
show the reaction diagram
-
-
-
-
?
4-aminoestrone 3,4-diacetate + NADH
4-aminoestradiol 3,4-diacetate + NAD+
show the reaction diagram
-
-
-
-
?
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
show the reaction diagram
4-methyl-1,3,5(10)-estratriene-1,17beta-diol + NAD+
1-hydroxy-4-methyl-1,3,5(10)-estratriene-17-one + NADH
show the reaction diagram
-
-
-
-
?
4-nitrestrone + NADH
4-nitroestradiol + NAD+
show the reaction diagram
-
-
-
-
r
4-nitroestradiol + NAD+
4-nitroestrone + NADH
show the reaction diagram
-
-
-
-
r
5,7,9-estratrien-3beta-ol-17-one + NADH
5,7,9-estratriene-3beta,17beta-diol + NAD+
show the reaction diagram
-
-
-
-
?
5,7,9-estratriene-3beta,17beta-diol + NAD+
5,7,9-estratriene-3beta-ol-17-one + NADH
show the reaction diagram
-
-
-
-
?
5-androstene-3beta,17beta-diol + NAD+
5-androstene-3-beta-ol-17-one + NADH
show the reaction diagram
-
5.9% of the activity with estradiol
-
-
?
5-androstene-3beta,17beta-diol + NAD+
? + NADH + H+
show the reaction diagram
-
-
-
-
?
5-androstene-3beta-ol-17-one + NADPH
5-androstene-3beta,17beta-diol + NADP+
show the reaction diagram
-
-
-
?
5alpha-adrostane-3alpha,17beta-diol + NAD+
androsterone + NADH + H+
show the reaction diagram
-
-
-
?
5alpha-androstane-3alpha,17beta-diol + NAD+
androsterone + NADH + H+
show the reaction diagram
-
-
-
?
5alpha-dihydrotestosterone + NAD+
5alpha-androstan-3,17-dione + NADH
show the reaction diagram
-
3.2% of the activity with estradiol
-
-
?
5alpha-dihydrotestosterone + NADP+
5alpha-androstan-3,17-dione + NADPH
show the reaction diagram
5alpha-dihydrotestosterone + NADPH + H+
5alpha-androstane-3beta,17beta-diol + 5alpha-androstane-3,17-dione + NADP+
show the reaction diagram
-
-
-
?
6-dehydroestrone 3-benzoate + NADH
6-dehydro-17beta-estradiol 3-benzoate + NAD+
show the reaction diagram
-
-
-
-
?
6-ketoestrone + NADH
6-ketoestradiol-17beta + NAD+
show the reaction diagram
-
-
-
-
?
6alpha,7alpha-dihydroxyestrone + NADH
6alpha,7alpha-dihydroxyestradiol + NAD+
show the reaction diagram
-
-
-
-
?
6alpha-hydroxyestradiol + NAD+
6alpha-hydroxyestrone + NADH
show the reaction diagram
-
-
-
-
?
7-ketoestrone + NADH
7-ketoestradiol-17beta + NAD+
show the reaction diagram
-
-
-
-
?
7alpha-hydroxyestradiol + NAD+
7alpha-hydroxyestrone + NADH
show the reaction diagram
-
-
-
-
?
7alpha-hydroxyestrone + NADH
7alpha-hydroxyestradiol + NAD+
show the reaction diagram
-
-
-
-
r
7beta-hydroxyestrone + NADH
7beta-hydroxyestradiol + NAD+
show the reaction diagram
-
-
-
-
?
9,10-phenanthrenequinone + NADPH
?
show the reaction diagram
-
-
-
-
?
androst-4-ene-3,17-dione + NADH + H+
testosterone + NAD+
show the reaction diagram
-
-
-
?
androst-4-ene-3,17-dione + NADPH
androst-4-ene-17beta-ol-3-one + NADP+
show the reaction diagram
-
-
-
-
-
androstenedione + NAD(P)H + H+
testosterone + NADP+
show the reaction diagram
-
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
show the reaction diagram
androsterone + NADH + H+
5alpha-adrostane-3alpha,17beta-diol + NAD+
show the reaction diagram
-
-
-
?
dehydroepiandrosterone + NAD(P)H
androst-5-ene-3beta,17beta-diol + NAD(P)+
show the reaction diagram
-
-
-
-
?
dehydroepiandrosterone + NADP+
?
show the reaction diagram
-
-
-
-
?
dehydroepiandrosterone + NADPH + H+
5-androstene-3beta,17beta-diol + NADP+
show the reaction diagram
-
-
-
-
?
dihydrotestosterone + NAD(P)H + H+
androstane-3beta,17beta-diol + NAD(P)+
show the reaction diagram
-
-
-
-
?
dihydrotestosterone + NADPH + H+
5alpha-androstane-3beta,17beta-diol + NADP+
show the reaction diagram
-
-
-
-
?
DL-3-deoxyequilenin + NADH
17beta-hydroxy-DL-3-deoxyequilin + NAD+
show the reaction diagram
-
-
-
-
?
DL-6-methoxy-3-deoxy-equilenin + NAD+
17beta-hydroxy-DL-6-methoxy-3-deoxyequilenin + NAD+
show the reaction diagram
-
-
-
-
?
equilenin + NADH
17beta-hydroxyequilenin + NAD+
show the reaction diagram
-
-
-
-
?
equilin + NADH
17beta-hydroxyequilin + NAD+
show the reaction diagram
-
-
-
-
?
estradiol + NAD(P)+
estrone + NAD(P)H
show the reaction diagram
-
-
-
-
?
estradiol + NAD+
estrone + NADH + H+
show the reaction diagram
-
-
-
-
?
estradiol + NADP+
estrone + NADPH
show the reaction diagram
-
the equilibrium state is 92% estradiol to 8% estrone
-
-
?
estradiol + NADP+
estrone + NADPH + H+
show the reaction diagram
-
-
-
-
?
estradiol-17beta + NAD(P)+
estrone + NAD(P)H
show the reaction diagram
estradiol-17beta + NAD(P)+
estrone + NAD(P)H + H+
show the reaction diagram
estradiol-17beta + NAD+
estrone + NADH
show the reaction diagram
estradiol-17beta + NAD+
estrone + NADH + H+
show the reaction diagram
estradiol-17beta + NADP+
estrone + NADPH
show the reaction diagram
estradiol-17beta + NADP+
estrone + NADPH + H+
show the reaction diagram
estrone + NAD(P)H
estradiol + NAD(P)+
show the reaction diagram
estrone + NAD(P)H
estradiol-17beta + NAD(P)+
show the reaction diagram
estrone + NAD(P)H + H+
estradiol + NAD(P)+
show the reaction diagram
estrone + NAD(P)H + H+
estradiol-17beta + NAD(P)+
show the reaction diagram
estrone + NADH
estradiol-17beta + NAD+
show the reaction diagram
estrone + NADH + H+
17beta-estradiol + NAD+
show the reaction diagram
-
-
-
?
estrone + NADH + H+
estradiol + NAD+
show the reaction diagram
-
-
-
-
?
estrone + NADH + H+
estradiol-17beta + NAD+
show the reaction diagram
estrone + NADPH
17beta-estradiol + NADP+
show the reaction diagram
estrone + NADPH
estradiol + NADP+ + H+
show the reaction diagram
-
-
-
-
?
estrone + NADPH + H+
17beta-estradiol + NADP+
show the reaction diagram
estrone + NADPH + H+
estradiol + NADP+
show the reaction diagram
-
-
-
-
?
estrone + NADPH + H+
estradiol-17beta + NADP
show the reaction diagram
-
-
-
-
?
estrone + NADPH + H+
estradiol-17beta + NADP+
show the reaction diagram
estrone 3-methyl ether + NADH
3-O-methyl-17beta-estradiol + NAD+
show the reaction diagram
-
-
-
-
?
estrone 3-oxyacetic acid ether + NADH
17beta-estradiol 3-O-oxyacetic acid ether + NAD+
show the reaction diagram
-
-
-
-
?
estronesulfate + NADPH
17beta-estradiolsulfate + NADP+
show the reaction diagram
-
-
-
-
r
progesterone + NADPH
? + NADP+
show the reaction diagram
-
low activity
-
-
?
S-tetralol + NADP+
?
show the reaction diagram
-
-
-
-
?
testosterone + NAD(P)+
4-androstene-3,17-dione + NAD(P)H
show the reaction diagram
-
17beta-HSD2 and 5, key role in regulating steroid receptor occupancy in normal and tumor tissues
-
-
?
testosterone + NAD+
4-androstene-3,17-dione + NADH
show the reaction diagram
-
2.4% of the activity with estradiol
-
-
?
testosterone + NAD+
? + NADH + H+
show the reaction diagram
-
-
-
-
?
testosterone + NAD+
androst-4-ene-3,17-dione + NADH + H+
show the reaction diagram
-
-
-
?
testosterone + NAD+
androstenedione + NAD(P)H + H+
show the reaction diagram
-
-
-
-
?
testosterone + NAD+
DELTA4-3,17-androstendione + NADH + H+
show the reaction diagram
-
-
-
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
show the reaction diagram
zymosterone + NAD(P)H
zymosterol + NAD(P)+
show the reaction diagram
Q5MGS6
-
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
17beta-estradiol + NAD(P)+
estrone + NAD(P)H + H+
show the reaction diagram
-
-
-
-
r
17beta-estradiol + NAD+
estrone + NADH + H+
show the reaction diagram
17beta-estradiol + NADP+
estrone + NADPH
show the reaction diagram
-
-
-
-
?
17beta-estradiol + NADP+
estrone + NADPH + H+
show the reaction diagram
C9JRZ8
-
-
-
?
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
show the reaction diagram
-
17beta-HSD3 and 5, formation of active androgens in testis and prostate
-
-
?
5alpha-androstane-3alpha,17beta-diol + NAD+
androsterone + NADH + H+
show the reaction diagram
C9JRZ8
-
-
-
?
5alpha-dihydrotestosterone + NADP+
5alpha-androstan-3,17-dione + NADPH
show the reaction diagram
Q5MGS6
the enzyme could play a critical role in estrogen-sensitive cells, since it inactivates 5alpha-dihydrotestosterone that generally shows antagonistic effect in the cells
-
-
?
androstenedione + NAD(P)H + H+
testosterone + NADP+
show the reaction diagram
P14016
-
-
-
?
estradiol-17beta + NAD(P)+
estrone + NAD(P)H
show the reaction diagram
-
17beta-HSD2 and 5, key role in regulating steroid receptor occupancy in normal and tumor tissues
-
-
?
estradiol-17beta + NAD(P)+
estrone + NAD(P)H + H+
show the reaction diagram
-
17beta-HSD4 is involved in etsrogen inactivation and may protect against an excessive accumulation of E2 in human ovarian epithelial cells
-
-
?
estradiol-17beta + NAD+
estrone + NADH
show the reaction diagram
-
-
-
-
-
estradiol-17beta + NAD+
estrone + NADH + H+
show the reaction diagram
-
vitamin K2 binds 17beta-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism. Vitamin K2 decreases the estradiol-17beta/estrone ratio in cells by 25%
-
-
?
estradiol-17beta + NADP+
estrone + NADPH
show the reaction diagram
-
17beta-HSD2, important role in peripheral inactivation of androgens and estrogens, 17beta-HSD4, low substrate affinity
-
-
?
estrone + NAD(P)H
estradiol + NAD(P)+
show the reaction diagram
-
normal and tubal pregancies possess identical expression of 17HSD1 in syncytiotrophoblast cells and therefore, similar estradiol production in the placenta. Association of 17HSD1 with extravillous cells indicates that the enzyme perhaps plays a role in trophoblast invasion.Increased expression of 17HSD1 in epithelial cells of fallopian tube may lead to a local estradiol supply sufficient for maintenance of tubal pregnancy
-
-
?
estrone + NAD(P)H
estradiol-17beta + NAD(P)+
show the reaction diagram
estrone + NAD(P)H + H+
estradiol + NAD(P)+
show the reaction diagram
estrone + NAD(P)H + H+
estradiol-17beta + NAD(P)+
show the reaction diagram
-
type 1 17beta-hydroxysteroid dehydrogenase plays a critical role in the biosynthesis of estradiol
-
-
?
estrone + NADH
estradiol-17beta + NAD+
show the reaction diagram
estrone + NADH + H+
17beta-estradiol + NAD+
show the reaction diagram
P37059
-
-
-
?
estrone + NADPH
17beta-estradiol + NADP+
show the reaction diagram
estrone + NADPH + H+
17beta-estradiol + NADP+
show the reaction diagram
-
-
-
-
?
estrone + NADPH + H+
estradiol-17beta + NADP+
show the reaction diagram
estronesulfate + NADPH
17beta-estradiolsulfate + NADP+
show the reaction diagram
-
-
-
-
r
testosterone + NAD(P)+
4-androstene-3,17-dione + NAD(P)H
show the reaction diagram
-
17beta-HSD2 and 5, key role in regulating steroid receptor occupancy in normal and tumor tissues
-
-
?
testosterone + NAD+
androstenedione + NAD(P)H + H+
show the reaction diagram
-
-
-
-
?
testosterone + NAD+
DELTA4-3,17-androstendione + NADH + H+
show the reaction diagram
C9JRZ8
-
-
-
?
testosterone + NADP+
4-androstene-3,17-dione + NADPH + H+
show the reaction diagram
-
17beta-HSD2, important role in peripheral inactivation of androgens and estrogens
-
-
?
additional information
?
-
-
the isozymes constitute by showing different properties a complex system ensuring cell-specific adaptation and regulation of sex steroid hormone levels, isozyme 17beta-HSD1 is the major determinant of peripheral and gonadal estradiol synthesis
-
-
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
NAD(P)H
-
-
NADP+
NADPH
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(10R,13S,17R)-10,13-dimethyl-1,2,7,8,9,10,11,12,13,14,15,16-dodecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5',6(4'H)-trione
-
0.003 mM, 45% inhibition, substrate: 4-androstene-3,17-dione
(10R,13S,17R)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'(2H,4'H)-dione
-
0.003 mM, 61% inhibition, substrate: 4-androstene-3,17-dione; 0.003 mM, 63% inhibition, substrate: 4-androstene-3,17-dione
(13alpha)-3-hydroxyestra-1(10),2,4-trien-17-one
-
inhibits the enzyme activity effectively, enzyme affinity is similar to that of the natural estrone substrate
(13S,17R)-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-3,5'-diol
-
0.003 mM, 61% inhibition, substrate: 4-androstene-3,17-dione
(13S,17R)-3-hydroxy-13-methyl-3',4',6,7,8,9,11,12,13,14,15,16-dodecahydro-5'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-5'-one
-
0.003 mM, 79% inhibition, substrate: 4-androstene-3,17-dione
(13S,17R)-3-hydroxy-13-methyl-5'-propyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 83% inhibition, substrate: 4-androstene-3,17-dione
(13S,17R)-3-hydroxy-5',13-dimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 94% inhibition, substrate: 4-androstene-3,17-dione
(13S,17R)-5',13-dimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 94% inhibition, substrate: 4-androstene-3,17-dione
(13S,17R)-5',5',13-trimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 95% inhibition, substrate: 4-androstene-3,17-dione
(13S,17S)-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 95% inhibition, substrate: 4-androstene-3,17-dione
(13S,17S)-3-hydroxy-13-methyl-3',4',6,7,8,9,11,12,13,14,15,16-dodecahydro-5'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-5'-one
-
0.003 mM, 45% inhibition, substrate: 4-androstene-3,17-dione
(13S,17S)-3-hydroxy-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 95% inhibition, substrate: 4-androstene-3,17-dione
(13S,17S)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydro-7'H-spiro[cyclopenta[a]phenanthrene-17,2'-oxepan]-7'-one
-
0.003 mM, 93% inhibition, substrate: 4-androstene-3,17-dione
(15alpha)-3-hydroxy-N-(5-methyl-1,3-thiazol-2-yl)-17-oxoestra-1(10),2,4-triene-15-carboxamide
-
-
(15beta)-15-(4-morpholin-4-yl-4-oxobutyl)-17-oxoestra-1(10),2,4-trien-3-yl sulfamate
-
0.0001 mM, 10% inhibition
(15beta)-3-hydroxy-15-(3-hydroxypropyl)estra-1(10),2,4-trien-17-one
-
-
(15beta)-3-hydroxy-15-(5-hydroxypentyl)estra-1(10),2,4-trien-17-one
-
-
(16alpa,17beta)-16-(3-bromopropyl)estra-1(10),2,4-triene-3,17-diol
-
EM-251
(16alpha)-2-chloro-16-fluoro-3-hydroxyestra-1(10),2,4-trien-17-one
-
-
(16alpha)-3-hydroxy-17-oxoestra-1(10),2,4-triene-16-carbonitrile
-
-
(16beta)-16-(ethoxymethyl)-3-hydroxyestra-1(10),2,4-trien-17-one
-
-
(16beta)-2-chloro-16-fluoro-3-hydroxyestra-1(10),2,4-trien-17-one
-
-
(16beta)-3-hydroxy-16-methyl-17-oxoestra-1(10),2,4-triene-16-carbonitrile
-
-
(16beta)-3-hydroxy-17-oxoestra-1(10),2,4-triene-16-carbonitrile
-
-
(16Z)-3-hydroxy-16-(2,2,2-trifluoro-1-hydroxyethylidene)estra-1(10),2,4-trien-17-one
-
-
(16Z)-3-hydroxy-16-(hydroxymethylidene)estra-1(10),2,4-trien-17-one
-
-
(17beta)-3,17-dihydroxy-N-(pyridin-3-ylmethyl)estra-1(10),2,4-triene-16-carboxamide
-
-
(17E)-3-hydroxyestra-1(10),2,4-trien-17-one oxime
-
-
(17Z)-3-hydroxyestra-1(10),2,4-triene-16,17-dione dioxime
-
-
(1Z)-N'-[[(3,5-dimethylisoxazol-4-yl)carbonyl]oxy]-2-[4-(1,2,3-thiadiazol-4-yl)phenyl]ethanimidamide
-
-
(2'R,13S)-3-hydroxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 92% inhibition, substrate: 4-androstene-3,17-dione
(2'R,13S)-3-hydroxy-4',13-dimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 94% inhibition, substrate: 4-androstene-3,17-dione
(2'R,13S)-3-hydroxy-5',5',13-trimethyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 94% inhibition, substrate: 4-androstene-3,17-dione
(2'R,13S)-5'-cyclopropyl-3-hydroxy-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
0.003 mM, 91% inhibition, substrate: 4-androstene-3,17-dione
(2'R,13S)-methyl 3-hydroxy-13-methyl-6'-oxo-3',4',5',6,6',7,8,9,11,12,13,14,15,16-tetradecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-5'-carboxylate
-
0.003 mM, 92% inhibition, substrate: 4-androstene-3,17-dione
(2,4-dihydroxyphenyl)-phenylmethanone
-
-
(2E)-3-[2-hydroxy-6-(3-hydroxyphenyl)-1-naphthyl]-N-methylacrylamide
-
58% inhibition at 0.001 mM
(2E)-3-[2-hydroxy-6-(3-hydroxyphenyl)-1-naphthyl]-N-phenylacrylamide
-
60% inhibition at 0.001 mM
(2R,4aS,4bR,10bS,12aS)-9-chloro-2-fluoro-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
-
(2S,4aS,4bR,10bS,12aS)-9-chloro-2-fluoro-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
-
(2Z,2'E)-N,N'-1H-1,5-benzodiazepine-2,4-diylbis(3-phenylprop-2-enamide)
-
30% inhibition at 0.006 mM
(3-amino-5-[13-[(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]tridecyl]phenyl)acetic acid
-
-
(3-[(4-aminophenyl)carbonyl]-5-[13-[(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]tridecyl]phenyl)acetic acid
-
-
(3-[13-[(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]tridecyl]phenyl)acetic acid
-
-
(3alpha,7alpha,17beta)-17-ethynyl-7-methylestr-5(10)-ene-3,17-diol
-
-
(3beta,7alpha,17beta)-17-ethynyl-7-methylestr-5(10)-ene-3,17-diol
-
-
(4aS,4bR,10bS,12aS)-8-hydroxy-12a-methyl-9-(2-phenylethyl)-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
-
(4aS,4bR,10bS,12aS)-8-hydroxy-12a-methyl-9-prop-2-en-1-yl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
-
(4aS,4bR,10bS,12aS)-8-hydroxy-9-iodo-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
-
(4aS,4bR,10bS,12aS)-8-hydroxy-9-methoxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
-
(4aS,4bR,10bS,12aS)-9-bromo-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
-
(4aS,4bR,10bS,12aS)-9-chloro-8-hydroxy-12a-methyl-3,4,4a,4b,5,6,10b,11,12,12a-decahydrochrysen-1(2H)-one
-
-
(4R,5R)-4-(2-fluorophenyl)-5-[hydroxy(5-phenylthiophen-2-yl)methyl]-1-methylpyrrolidin-2-one
-
-
(4R,5R)-5-[hydroxy[5-(pyridin-3-yl)thiophen-2-yl]methyl]-1-methyl-4-phenylpyrrolidin-2-one
-
-
(4S,5S)-5-[biphenyl-3-yl(hydroxy)methyl]-4-(2-fluorophenyl)-1-methylpyrrolidin-2-one
-
;
(4S,5S)-5-[biphenyl-4-yl(hydroxy)methyl]-4-(2-fluorophenyl)-1-methylpyrrolidin-2-one
-
;
(4S,5S)-5-[hydroxy[5-(pyridin-3-yl)thiophen-2-yl]methyl]-1-methyl-4-phenylpyrrolidin-2-one
-
;
(6-hydroxy-1,3-benzothiazol-2-yl)(3-hydroxyphenyl)methanone
-
modeling of binding to crystal structure shows five hydrogen bond interactions and a cation-pi-interaction
(6aS)-2-(benzyloxy)-6a-methyl-9-[(2E)-4-morpholin-4-yl-4-oxobut-2-en-1-yl]-5,6,6a,10,10a,10b,11,12-octahydro-4bH-naphtho[2',1':4,5]indeno[2,1-d]isoxazole
-
0.0001 mM, 21% inhibition
(6aS)-2-hydroxy-6a,8-dimethyl-5,6,6a,7,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-9(4bH)-one
-
0.01 mM, 32% inhibition
(6aS)-2-hydroxy-6a-methyl-5,6,6a,7,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-9(4bH)-one
-
0.01 mM, 86% inhibition
(6aS)-2-hydroxy-6a-methyl-N-(2-pyridin-3-ylethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
(6aS)-2-hydroxy-6a-methyl-N-(pyridin-2-ylmethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
(6aS)-2-hydroxy-6a-methyl-N-(pyridin-3-ylmethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
(6aS)-2-hydroxy-6a-methyl-N-[(1-methyl-1H-pyrrol-2-yl)methyl]-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
-
0.01 mM, 90% inhibition, IC50: 0.0023 mM
(6aS)-2-hydroxy-6a-methyl-N-[(5-methylpyrazin-2-yl)methyl]-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
-
0.01 mM, 80% inhibition
(6aS)-3-ethyl-2-hydroxy-6a-methyl-N-(2-pyridin-3-ylethyl)-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-9-carboxamide
-
-
(6aS)-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
-
-
(6aS)-6a-methyl-9-(4-morpholin-4-yl-4-oxobutyl)-4b,5,6,6a,7,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
-
0.0001 mM, 53% inhibition
(6aS)-6a-methyl-9-(trifluoromethyl)-4b,6,6a,7,9a,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazole-2,6b(5H)-diol
-
-
(6aS)-8-(2-methoxyethyl)-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
-
-
(6aS)-9-(hydroxymethyl)-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
-
-
(6aS,6bR,10aR)-2-hydroxy-6a-methyl-5,6,6a,6b,9,10,10a,11,11a,11b,12,13-dodecahydronaphtho[2',1':4,5]indeno[1,2-b]pyran-8(4bH)-one
-
0.003 mM, 52% inhibition, substrate: 4-androstene-3,17-dione
(6aS,6bS,10aS)-2-hydroxy-6a-methyl-5,6,6a,6b,9,10,10a,11,11a,11b,12,13-dodecahydronaphtho[2',1':4,5]indeno[1,2-b]pyran-8(4bH)-one
-
0.003 mM, 85% inhibition, substrate: 4-androstene-3,17-dione
(6aS,6bS,11aS)-2-hydroxy-6a-methyl-4b,5,6,6a,6b,9,10,11,11a,12,12a,12b,13,14-tetradecahydro-8H-naphtho[2',1':4,5]indeno[1,2-b]oxepin-8-one
-
0.003 mM, 91% inhibition, substrate: 4-androstene-3,17-dione
(6aS,6bS,9aR)-2-hydroxy-6a-methyl-4b,5,6,6a,6b,9,9a,10,10a,10b,11,12-dodecahydro-8H-naphtho[2',1':4,5]indeno[1,2-b]furan-8-one
-
0.003 mM, 62% inhibition, substrate: 4-androstene-3,17-dione
(6beta,17beta)-6-(hexylsulfanyl)estra-1(10),2,4-triene-3,17-diol
-
-
(6Z,17E)-3-hydroxyestra-1(10),2,4-triene-6,17-dione dioxime
-
-
(7alpha,17beta)-17-ethynyl-17-hydroxy-7-methylestr-4-en-3-one
-
-
(8R,9S,13S,14S,17S)-3-hydroxy-13-methyl-4',5',6,7,8,9,11,12,13,14,15,16-dodecahydrospiro[cyclopenta[a]phenanthrene-17,2'-pyran]-6'(3'H)-one
-
85% inhibition at 0.001 mM
(S)-2-Methoxy-6a-methyl-5,6,6a,10,10a,10b,11,12-octahydro-4bH-7-oxa-8-aza-pentaleno[2,1-a]phenanthrene
-
-
(S)-6a-Methyl-5,6,6a,10,10a,10b,11,12-octahydro-4bH-7-oxa-8-aza-pentaleno[2,1-a]phenanthren-2-ol
-
-
1'(2')H-estra-1,3,5(10)-trieno[17,16-c]pyrazol-3-ol
-
IC50: 0.0041 mM
1,1':4',1''-terphenyl-3,3''-diol
-
-
1,2,3,4-tetrahydroquinolin-7-yl 4-(acetylamino)benzenesulfonate
-
-
1,2-Cyclohexanedione
-
40 mM, pH 8.5, t1/2: 4.4 h
1,3,5(10),16-estratetraen-3-ol
-
-
1,3,5(10)-estratrien-3,16beta,17beta-triol
-
-
1,3,5(10)-estratrien-3,16beta-diol
-
-
1,3,5(10)-estratrien-3,17alpha-diol
-
-
1,3,5(10)-estratrien-3-ol
-
-
1,4-dibromo-2,3-butanedione
-
40 mM, pH 8.5, t1/2: 0.02 h
1,9-decanediol
-
-
1-(3'-ethyl-4'-hydroxy-biphenyl-4-yl)-ethanone
1-(3-ethyl-4'-hydroxy-biphenyl-4-yl)-ethanone
1-(4'-hydroxy-2'-methyl-biphenyl-4-yl)-ethanone
-
89% inhibition at 0.001 mM
1-(4'-hydroxy-2'_methyl-biphenyl-4-yl)-ethanone
-
37°C, 0.01 mM, 89% inhibition, substrate: estrone, 7beta-HSD type 1
1-(4'-hydroxy-biphenyl-4-yl)-ethanone
-
37°C, 01 mM, 97% inhibition, substrate: estrone, 7beta-HSD type 1; 97% inhibition at 0.001 mM
1-(4-fluorophenyl)-3-[4-(1,2,3-thiadiazol-4-yl)benzyl]urea
-
-
1-(6-hydroxy-9H-fluoren-2-yl)-ethanone
-
37°C, 0.01 mM, 86% inhibition, substrate: estrone, 7beta-HSD type 1; 86% inhibition at 0.001 mM
1-bromo-6-(3-hydroxyphenyl)-2-naphthol
-
88% inhibition at 0.001 mM
1-Chloro-4-(2,2-dichloro-1-(5-Chloro-phenyl)-ethyl)-benzene
-
oxidation of estradiol
1-Chloro-4-(2,2-dichloro-1-(6-Chloro-phenyl)-ethyl)-benzene
-
oxidation of estradiol
1-phenyl-1,2-propanedione
-
40 mM, pH 8.5, t1/2: 0.19 h
1-[(3-hydroxyphenyl)sulfanyl]-5-oxo-4,5,7,8,9,10,11,13-octahydro-3H-indeno[2',1':4,5]pyrimido[1,2-a]azepine-2-carbaldehyde
-
-
1-[2-[4-(6-Methoxy-2-phenyl-3,4-dihydro-naphthalen-1-yl)-phenoxy]-ethyl]-pyrrolidine
-
oxidation of estradiol
1-[5-(3'-hydroxybiphenyl-3-yl)-2-thienyl]ethanone
-
0.001 mM, 10 min, 22% inhibition; 0.001 mM, 10 min, 23% inhibition
1-[5-(3'-Hydroxybiphenyl-4-yl)-2-thienyl]ethanone
-
0.001 mM, 10 min, 10% inhibition; 0.001 mM, 10 min, 38% inhibition
10-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-decanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester
-
IC50: 140 nM
11-((13S,17R)-17-Ethynyl-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-undecanoic acid butyl-methyl-amide
-
-
13-oxo-4-(phenylsulfanyl)-1,2,7,8,9,10,11,13-octahydro[1]benzothieno[2',3':4,5]pyrimido[1,2-a]azepine-3-carbaldehyde
-
0.001 mM, 80% inhibition
13-oxo-4-(propylsulfanyl)-1,2,7,8,9,10,11,13-octahydro[1]benzothieno[2',3':4,5]pyrimido[1,2-a]azepine-3-carbaldehyde
-
0.001 mM, 74% inhibition
16-cyano-17-oxoestra-1(10),2,4-trien-3-yl sulfamate
-
-
16-cyano-2-methoxy-17-oxoestra-1(10),2,4-trien-3-yl sulfamate
-
-
16-difluoro-estradiol
-
oxidation of estradiol
16-methylen-estra-1,3,5(10)-triene-3,17beta-diol
-
suicide inhibitor
16-oxo-estrone
-
40 mM, pH 8.5, t1/2: 0.8-1 h, at pH 7.2 inhibition is competitive against estradiol and non-competitive against NAD+
16alpha-bromobutyl-estradiol
-
-
16alpha-bromopropyl-estradiol
-
IC50: 0.00046 mM, reduction of estrone, the inhibitor is totally inactive against type 2 17beta-HSD and type type 1 17beta-HSD
16beta-bromobutyl-estradiol
-
-
16beta-m-pyridylmethylamidomethyl-2-methoxyoestrone
-
IC50: 0.00029 mM
17(R,S)-14,15-secoestra-1,3,5(10)-trien-15-yne-3,17-diol
-
suicide inhibitor
17-(1-hydroxy-prop-2-ynyl)-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
-
suicide inhibitor
17-deoxy-estradiol
-
oxidation of estradiol
2',4',4-trihydroxy-4'-chalcone
-
IC50: 0.0338 mM
2',4'-dihydroxy-chalcone
-
IC50: 0.0346 mM
2',5'-ADP
-
-
2'-AMP
-
competitive with respect to NAD(H) or NADP(H) and noncompetitive with respect to the steroid
2'-methoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-sulfonamide
-
; 23% inhibition at 0.001 mM
2'-methoxy-N-methyl-N-phenyl-[1,1'-biphenyl]-4-sulfonamide
-
; 10% inhibition at 0.001 mM
2,2',4,4'-tetrahydroxybenzophenone
-
-
2,2'-diimino-7,7'-dimethyl-5,5'-bis(1-methylethyl)-2H,2'H-8,8'-binaphtho[1,8-bc]furan-3,3',4,4'-tetrol
-
-
2,3-Butanedione
-
40 mM, pH 8.5, t1/2: 2 h
2,3-Pentanedione
-
40 mM, pH 8.5, t1/2: 5.3 h
2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate
-
44% inhibition at 0.006 mM
2-(2,6-dibromo-4-methylphenoxy)-N'-[(E)-(2,4-dihydroxy-6-methylphenyl)methylidene]acetohydrazide
-
64% inhibition at 0.02 mM
2-(2,6-dibromo-4-methylphenoxy)-N'-[(E)-(2,4-dimethoxyphenyl)methylidene]acetohydrazide
-
38% inhibition at 0.02 mM
2-(2-bromo-4,6-dimethylphenoxy)-N'-[(E)-(2,4-dihydroxyphenyl)methylidene]acetohydrazide
-
91% inhibition at 0.02 mM
2-(2-bromo-4-methylphenoxy)-N'-[(1E)-1-(2,4-dihydroxyphenyl)ethylidene]acetohydrazide
-
-
2-(3-hydroxyphenyl)quinolin-6-ol
-
0.001 mM, 63% inhibition, substrate: estrone
2-(acetylamino)phenyl 3,4-dimethylbenzenesulfonate
-
-
2-chloro-3-hydroxyestra-1(10),2,4-trien-17-one
-
-
2-ethyl-17-oxo-16-[2-oxo-2-[(pyridin-3-ylmethyl)amino]ethyl]estra-1(10),2,4-trien-3-yl sulfamate
-
-
2-ethyl-3-sulfamoyloxy-17-oxo-estra-1,3,5(10)-trien-16-methylcarboxylic acid-S-alpha-methylbenzyl amide
-
50% inhibition at 0.001 mM
2-ethyl-3-sulfamoyloxy-17-oxo-estra-1,3,5(10)-trien-16alpha/beta-methylcarboxylic acid-(5-methylpyrimidinyl-2-ylmethyl)amide
-
37% inhibition at 0.001 mM
2-ethyl-3-sulfamoyloxy-17-oxo-estra-1,3,5(10)-trien-16alpha/beta-methylcarboxylic acid-(pyridine-3-ylmethyl)amide
-
64% inhibition at 0.01 mM
2-hydroxy-6-(3-hydroxyphenyl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)-1-naphthamide
-
73% inhibition at 0.001 mM
2-hydroxy-6-(3-hydroxyphenyl)-N-methyl-1-naphthamide
-
76% inhibition at 0.001 mM
2-hydroxy-6-(3-hydroxyphenyl)-N-phenyl-1-naphthamide
-
80% inhibition at 0.001 mM
2-hydroxy-N,6-bis(3-hydroxyphenyl)-1-naphthamide
-
70% inhibition at 0.001 mM
2-methoxyoestrone
-
IC50: 0.0024 mM
2-methoxyphenyl 3-(acetylamino)benzenesulfonate
-
-
2-methoxyphenyl benzenesulfonate
-
51% inhibition at 0.02 mM
2-methylcinnamic acid
-
IC50: 0.0064 mM
2-nitrophenyl (2E)-3-phenylprop-2-enoate
-
45% inhibition at 0.006 mM
2-[(16beta)-2-ethyl-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-3-ylmethyl)acetamide
-
-
2-[2-ethyl-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-2-ylmethyl)acetamide
-
-
2-[2-ethyl-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-3-ylmethyl)acetamide
-
-
2-[3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(2-pyridin-2-ylethyl)acetamide
-
0.01 mM, 58% inhibition
2-[3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-2-ylmethyl)acetamide
-
0.01 mM, 82% inhibition
2-[3-hydroxy-17-oxoestra-1(10),2,4-trien-16-yl]-N-(pyridin-3-ylmethyl)acetamide
-
-
2-[5-(3-ethyl-4-hydroxyphenyl)-1-oxo-indan-2-yl]-N-pyridin-3-ylmethyl-acetamide
-
37°C, 0.001 mM, 39% inhibition, substrate: estrone, 7beta-HSD type 1; 39% inhibition at 0.001 mM
3',4',5,7-tetrahydroxy-flavone
-
IC50: 0.0006 mM
3',4',7-trihydroxy-isoflavone
-
IC50: 0.0052 mM
3',5'-ADP
-
-
3'-(1-benzothien-2-yl)biphenyl-3-ol
-
0.001 mM, 10 min, 39% inhibition; 0.001 mM, 10 min, 49% inhibition
3'-(2-thienyl)biphenyl-3-ol
-
0.001 mM, 10 min, 40% inhibition; 0.001 mM, 10 min, 48% inhibition
3'-(5-chloro-2-thienyl)biphenyl-3-ol
-
0.001 mM, 10 min, 31% inhibition; 0.001 mM, 10 min, 71% inhibition
3'-(5-methyl-2-thienyl)biphenyl-3-ol
-
0.001 mM, 10 min, 32% inhibition; 0.001 mM, 10 min, 36% inhibition
3'-hydroxy-N-(3-hydroxybenzyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
-
; 57% inhibition at 0.001 mM
3'-hydroxy-N-(3-hydroxybenzyl)-N-methylbiphenyl-3-carboxamide
-
-
3'-hydroxy-N-(3-hydroxybenzyl)-N-methylbiphenyl-4-carboxamide
-
;
3'-hydroxy-N-(3-hydroxyphenyl)-N-methyl-[1,10-biphenyl]-3-sulfonamide
-
42% inhibition at 0.001 mM; 68% inhibition at 0.001 mM
3'-hydroxy-N-(3-hydroxyphenyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
-
14% inhibition at 0.001 mM; 50% inhibition at 0.001 mM
3'-hydroxy-N-(3-hydroxyphenyl)-N-methylbiphenyl-3-carboxamide
-
35% inhibition
3'-hydroxy-N-(3-hydroxyphenyl)-N-methylbiphenyl-4-carboxamide
3'-hydroxy-N-(3-methoxyphenyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
-
15% inhibition at 0.001 mM; 38% inhibition at 0.001 mM
3'-methoxy-N-(2-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-sulfonamide
-
10% inhibition at 0.001 mM; 17% inhibition at 0.001 mM
3'-methoxy-N-(3-methoxybenzyl)-N-methyl-[1,10-biphenyl]-4-sulfonamide
-
; 45% inhibition at 0.001 mM
3'-methoxy-N-(3-methoxybenzyl)-N-methylbiphenyl-3-carboxamide
-
11% inhibition
3'-methoxy-N-(3-methoxybenzyl)-N-methylbiphenyl-4-carboxamide
-
;
3'-methoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-sulfonamide
-
10% inhibition at 0.001 mM; 27% inhibition at 0.001 mM
3'-methoxy-N-(3-methoxyphenyl)-N-methyl-[1,10-biphenyl]-3-sulfonamide
-
; 26% inhibition at 0.001 mM
3'-methoxy-N-(3-methoxyphenyl)-N-methylbiphenyl-3-carboxamide
-
-
3'-methoxy-N-(3-methoxyphenyl)-N-methylbiphenyl-4-carboxamide
-
; 35% inhibition at 0.001 mM
3'-methoxy-N-(4-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-sulfonamide
-
; 22% inhibition at 0.001 mM
3,3',4',7-tetrahydroxy-flavone
-
-
3,3',4,4'-tetrahydroxy-7,7'-dimethyl-5,5'-bis(1-methylethyl)-2H,2'H-8,8'-binaphtho[1,8-bc]furan-2,2'-dione
-
-
3,3'-(1-methyl-1H-1,2,4-triazole-3,5-diyl)diphenol
-
-
3,3'-(1-phenyl-1H-1,2,4-triazole-3,5-diyl)diphenol
-
-
3,3'-(1H-1,2,3-triazole-1,4-diyl)diphenol
-
; 17% inhibition at 0.001 mM
3,3'-pyridine-2,5-diyldiphenol
-
-
3,4,5-trimethoxycinnamic acid
3,5,7-trihydroxy-4'-methoxy-flavone
-
IC50: 15 mM
3,5,7-trihydroxy-flavone
-
-
3,5-dibromosalicylic acid
-
-
3-(17beta-hydroxy-3-methoxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
-
0.01 mM, 90% inhibition, substrate: estrone
3-(17beta-hydroxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
-
0.01 mM, 79% inhibition, substrate: estrone
3-(2-furylmethyl)-8-hydroxy-2-(2-phenylethyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
33% inhibition at 100 nM, 78% inhibition at 0.001 mM
3-(2-naphthyl)phenol
-
0.001 mM, 61% inhibition, substrate: estrone
3-(3,17beta-dihydroxy-2-methoxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
-
0.01 mM, 81% inhibition, substrate: estrone
3-(3,17beta-dihydroxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
-
0.001 mM, 94% inhibition, substrate: estrone
3-(3-hydroxy-17-oxo-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
-
0.001 mM, 88% inhibition, substrate: estrone
3-(3-hydroxyphenyl)quinolin-7-ol
-
0.001 mM, 57% inhibition, substrate: estrone
3-(3-methoxy-17-oxo-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
-
0.01 mM, 76% inhibition, substrate: estrone
3-(6-hydroxy-2-naphthyl)benzoic acid
-
0.001 mM, 76% inhibition, substrate: estrone
3-(hydroxymethyl)-4-(phenylsulfanyl)-2,7,8,9,10,11-hexahydro[1]benzothieno[2',3':4,5]pyrimido[1,2-a]azepin-13(1H)-one
-
0.001 mM, 52% inhibition
3-(quinolin-3-yl)phenol
-
0.001 mM, 18% inhibition, substrate: estrone
3-(trifluoromethyl)-cinnamic acid
-
-
3-([(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]methyl)benzamide
-
-
-
3-([(16beta,17beta)-3-(2-bromoethyl)-17-hydroxyestra-1(10),2,4-trien-16-yl]methyl)benzamide
-
a potent and steroidal nonestrogenic inhibitor of 17beta-HSD1, inhibits the transformation of estrone into estradiol by 17beta-HSD1 in T-47D cells. The comppound does not inhibit enzymes 17beta-HSD2, 17beta-HSD7, 17beta-HSD12, and CYP3A4, and does not stimulate the proliferation of estrogen-sensitive MCF-7 cells. Kinetic and molecular modeling (docking) experiments show that compound is a competitive and irreversible inhibitor of 17beta-HSD1
-
3-acetyl-2-oxo-2H-chromen-7-yl trifluoromethanesulfonate
-
IC50 value of 360 nM against recombinant enzyme in bacterial homogenate
3-acetyl-7-(4-hydroxyphenyl)-2H-chromen-2-one
-
IC50 value of 270 nM against recombinant enzyme in bacterial homogenate, and high selectivity for isoform 17beta-HSD1 over 17beta-HSD2 and against the alpha and beta estrogen receptors
3-benzyl-2-(2-bromo-3,4,5-trimethoxyphenyl)-8-hydroxy[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
3-benzyl-8-hydroxy-2-(2-methylprop-1-en-1-yl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
82% inhibition at 100 nM, 97% inhibition at 0.001 mM
3-benzyl-8-hydroxy-2-(2-thienyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
83% inhibition at 100 nM, 89% inhibition at 0.001 mM
3-benzyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
3-benzyl-8-hydroxy-2-(3-methoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
89% inhibition at 100 nM, 95% inhibition at 0.001 mM
3-benzylidene camphor
-
-
3-bromo-5-phenylsalicylic acid
-
-
3-bromo-N-(3-hydroxy-4-methylphenyl)benzenesulfonamide
-
-
3-butyl-8-hydroxy-2-(3,4,5-trimethoxybenzyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
0.001 mM,k 95% inhibition
3-butyl-8-hydroxy-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
86% inhibition at 100 nM, 95% inhibition at 0.001 mM
3-coumaric acid
-
34% inhibition at 0.05 mM
3-cyclohexylpropanoic acid
-
weak inhibition, IC50: 0.1 mM, above
3-hydroxy-1,3,5(10)-triene-[17,16-c]-(5'-carboxylic acid)-pyrazole
-
0.01 mM: 32% inhibition
3-hydroxy-1,3,5(10)-triene-[17,16-c]-(5'-hydroxymethyl)-pyrazole
-
0.01 mM: 94% inhibition, IC50: 0.00095 mM
3-hydroxy-1,3,5(10)-triene-[17,16-c]-[5'-(carboxylic acid ethyl ester)]-pyrazole
-
0.01 mM: 94% inhibition, IC50: 0.00185 mM
3-hydroxy-13alpha-D-secooxime
-
displays an outstanding cofactor dependence, i.e. more efficient inhibition in the presence of NADH than NADPH
3-hydroxy-13beta-D-secoalcohol
-
displays an outstanding cofactor dependence, i.e. more efficient inhibition in the presence of NADH than NADPH
-
3-hydroxy-17-oxoestra-1(10),2,4-triene-16-carboxylic acid
-
-
3-hydroxy-17-oxoestra-1(10),2,4-triene-2-carbonitrile
-
-
3-hydroxy-2-methoxy-17-oxoestra-1(10),2,4-triene-16-carbonitrile
-
0.01 mM, 35% inhibition
3-hydroxy-7-(3-hydroxyphenyl)-1-naphthonitrile
-
99% inhibition at 0.001 mM
3-hydroxy-7-(3-hydroxyphenyl)-N-methyl-2-naphthamide
-
18% inhibition at 0.001 mM
3-hydroxy-7-(3-hydroxyphenyl)-N-phenyl-2-naphthamide
-
62% inhibition at 0.001 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-isobutyl)-pyrazole
-
0.01 mM: 77% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-methoxyethyl)-pyrazole
-
0.01 mM: 95% inhibition, IC50: 0.00053 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-methyl acetate)-pyrazole
-
0.01 mM: 95% inhibition, IC50: 0.00092 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-methyl)-pyrazole
-
0.01 mM: 94% inhibition, IC50: 0.00275 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(1'-propionitrile)-pyrazole
-
0.01 mM: 95% inhibition, IC50: 0.00073 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(2'-isobutyl)-pyrazole
-
0.01 mM: 70% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(2'-methoxy-ethyl)-pyrazole
-
0.01 mM: 83% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(2'-methyl acetate)-pyrazole
-
0.01 mM: 79% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(2'-methyl)-pyrazole
-
0.01 mM: 43% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(5'-ethylme-thylcarbamoyl)-pyrazole
-
0.01 mM: 88% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(5'-isopropylcarbamoyl)-pyrazole
-
0.01 mM: 57% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(5'-methyl)-pyrazole
-
0.01 mM: 75% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-(5'-methyl-carbamoyl)-pyrazole
-
0.01 mM: 62% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(1''-methylpiperazin-4''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 50% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(1'-methylpyrrol-2''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 89% inhibition, IC50: 0.0023 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(5''-methylpyrazin-2''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 80% inhibition
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(pyridin-2''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 93% inhibition, IC50: 0.00088 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(pyridin-3''-ylethyl)carbamoyl]-pyrazole
-
0.01 mM: 99% inhibition, IC50: 0.0003 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(pyridin-3''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 92% inhibition, IC50: 0.00078 mM
3-hydroxy-estra-1,3,5(10)-triene-[17,16-c]-[5'-(tetrahydrofuran-2''-ylmethyl)carbamoyl]-pyrazole
-
0.01 mM: 87% inhibition
3-hydroxy-N-(3'-hydroxy-[1,1'-biphenyl]-3-yl)-N-methylbenzenesulfonamide
-
17% inhibition at 0.001 mM; 88% inhibition at 0.001 mM
3-hydroxy-N-(3'-hydroxy-[1,1'-biphenyl]-4-yl)-N-methylbenzenesulfonamide
-
22% inhibition at 0.001 mM; 66% inhibition at 0.001 mM
3-hydroxy-N-(6-hydroxy-1,3-benzothiazol-2-yl)benzamide
-
modeling of binding to crystal structure shows five hydrogen bond interactions and a cation-pi-interaction
3-hydroxyestra-1(10),2,4-triene-16,17-dione 16-oxime
-
-
3-hydroxyestra-1,3,5(10),7-tetraen-17-one
-
IC50: 0.0019 mM, oxidation of estradiol
3-methoxy-1'(2')H-estra-1,3,5(10)-trieno[17,16-c]pyrazole
-
-
3-methoxy-N-(3'-methoxy-[1,1'-biphenyl]-3-yl)-N-methylbenzenesulfonamide
-
14% inhibition at 0.001 mM; 68% inhibition at 0.001 mM
3-methoxy-N-(3'-methoxy-[1,10-biphenyl]-4-yl)-Nmethylbenzenesulfonamide
-
18% inhibition at 0.001 mM; 25% inhibition at 0.001 mM
3-phenoxybenzyl (2E)-3-(1,3-benzodioxol-5-yl)prop-2-enoate
-
14% inhibition at 0.006 mM
3-phenoxybenzyl (2E)-3-phenylprop-2-enoate
-
13% inhibition at 0.006 mM
3-phenyl-5-bromosalicylic acid
-
-
3-trifluoromethylcinnamic acid
-
IC50: 0.043 mM
3-[(15beta)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-(4-methyl-1,3-thiazol-2-yl)propanamide
-
-
3-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-(5-methyl-1,3-thiazol-2-yl)propanamide
-
-
3-[(4-chlorophenyl)sulfanyl]-6-(2,4-dimethyl-1H-pyrrol-1-yl)pyridazine
-
-
3-[(4bS,6aS,6bR,10S,10aS,11aS,11bR)-9-hexyl-2,10a-dihydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,10a,11,11a,11b,12,13-tetradecahydronaphtho[20,10:4,5]indeno[2,1-][1,3]oxazin-10-yl]benzamide
-
-
3-[(4bS,6aS,6bR,10S,10aS,11aS,11bR)-9-octyl-2,10a-dihydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,10a,11,11a,11b,12,13-tetradecahydronaphtho[20,10:4,5]indeno[2,1-][1,3]oxazin-10-yl]benzamide
-
-
3-[(4bS,6aS,6bR,10S,11aR,11bR)-9-butyl-2-hydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,11a,11b,12,13-dodecahydronaphtho[20,10:4,5]indeno[2,1-e][1,3]oxazin-10-l]benzamide
-
-
3-[(4bS,6aS,6bR,10S,11aR,11bR)-9-ethyl-2-hydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,11a,11b,12,13-dodecahydronaphtho[20,10:4,5]indeno[2,1-e][1,3]oxazin-10-l]benzamide
-
-
3-[(4bS,6aS,6bR,10S,11aR,11bR)-9-hexyl-2-hydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,11a,11b,12,13-dodecahydronaphtho[20,10:4,5]indeno[2,1-e][1,3]oxazin-10-l]benzamide
-
-
3-[(4bS,6aS,6bR,10S,11aR,11bR)-9-octyl-2-hydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,11a,11b,12,13-dodecahydronaphtho[20,10:4,5]indeno[2,1-e][1,3]oxazin-10-l]benzamide
-
-
3-[(5-bromofuran-2-yl)methyl]-8-hydroxy-2-(3,4,5-trimethoxybenzyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
0.001 mM, 95% inhibition
3-[(5-bromofuran-2-yl)methyl]-8-hydroxy-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
94% inhibition at 100 nM, 99% inhibition at 0.001 mM
3-[(6aS)-2-hydroxy-6a-methyl-4b,6,6a,10,10a,10b,11,12-octahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-8(5H)-yl]propanenitrile
-
-
3-[(6aS,6bR,10S,10aS)-9-butyl-2,10a-dihydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,10a,11,11a,11b,12,13-tetradecahydronaphtho[2',1':4,5]indeno[2,1-e][1,3]oxazin-10-yl]benzamide
-
-
3-[(6aS,6bR,10S,10aS)-9-ethyl-2,10a-dihydroxy-6a-methyl-8-oxo-4b,5,6,6a,6b,8,9,10,10a,11,11a,11b,12,13-tetradecahydronaphtho[2',1':4,5]indeno[2,1-e][1,3]oxazin-10-yl]benzamide
-
-
3-[1-(4-hydroxyphenyl)-1H-1,2,3-triazol-4-yl]-phenol
-
17beta-HSD1; substrate: estradiol-17beta, 17beta-HSD2
3-[1-(4-hydroxyphenyl)-1H-1,2,3-triazol-4-yl]phenol
-
-
3-[2-(2-thienyl)pyridin-4-yl]phenol
-
0.001 mM, 10 min, 33% inhibition; 0.001 mM, 10 min, 62% inhibition
3-[2-(5-chloro-2-thienyl)pyridin-4-yl]phenol
-
0.001 mM, 10 min, 39% inhibition; 0.001 mM, 10 min, 63% inhibition
3-[2-(5-chlorothiophen-2-yl)pyridin-4-yl]phenol
-
-
3-[2-hydroxy-6-(3-hydroxyphenyl)-1-naphthyl]-N-methylpropanamide
-
80% inhibition at 0.001 mM
3-[3-(4-hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-5-yl]phenol
-
-
3-[3-(4-hydroxyphenyl)-1-phenyl-1H-1,2,4-triazol-5-yl]phenol
-
-
3-[3-(4-hydroxyphenyl)isoxazol-5-yl]-phenol
-
17beta-HSD1; substrate: estradiol-17beta, 17beta-HSD2
3-[4-(4-hydroxyphenyl)-1,3-oxazol-2-yl]-phenol
-
17beta-HSD1
3-[4-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol
-
substrate: estradiol-17beta, 17beta-HSD2
3-[4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-yl]-phenol
-
17beta-HSD1; substrate: estradiol-17beta, 17beta-HSD2
3-[4-(4-hydroxyphenyl)-1H-1,2,3-triazol-1-yl]phenol
-
-
3-[4-(4-hydroxyphenyl)thiophen-2-yl]phenol
-
-
3-[4-(5-chloro-2-thienyl)pyridin-2-yl]phenol
-
0.001 mM, 10 min, 25% inhibition; 0.001 mM, 10 min, 61% inhibition
3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]-phenol
-
substrate: estradiol-17beta, 17beta-HSD2, very good selectivity, high cell permeability and medium CaCo-2 permeability; very good selectivity, high cell permeability and medium CaCo-2 permeability, 17beta-HSD1
3-[5-(4-hydroxyphenyl)-1-methyl-1H-1,2,4-triazol-3-yl]phenol
-
-
3-[5-(4-hydroxyphenyl)-1-phenyl-1H-1,2,4-triazol-3-yl]phenol
-
-
3-[5-(4-hydroxyphenyl)thiophen-2-yl]phenol
-
-
3-[5-(4-hydroxyphenyl)thiophen-3-yl]phenol
-
-
3-[5-(5-chloro-2-thienyl)pyridin-3-yl]phenol
-
0.001 mM, 10 min, 40% inhibition; 0.001 mM, 10 min, 46% inhibition
3-[6-(5-chloro-2-thienyl)pyridin-2-yl]phenol
-
0.001 mM, 10 min, 21% inhibition; 0.001 mM, 10 min, 40% inhibition
3beta-hydroxy-5,16-androstadiene
-
-
3beta-hydroxy-5-androsten-16-one
-
-
4',5,7-trihydroxy-flavanone
-
-
4',5,7-trihydroxy-flavone
-
IC50: 0.0003 mM
4',5,7-trihydroxy-isoflavone
-
IC50: 0.001 mM
4',7-dihydroxy-isoflavone
-
IC50: 0.01 mM
4'-(2-thienyl)biphenyl-3-ol
-
0.001 mM, 10 min, 22% inhibition; 0.001 mM, 10 min, 36% inhibition
4'-(3-furyl)biphenyl-3-ol
-
0.001 mM, 10 min, 17% inhibition
4'-(3-thienyl)biphenyl-3-ol
-
0.001 mM, 10 min, 36% inhibition; 0.001 mM, 10 min, 41% inhibition
4'-(5-chloro-2-thienyl)biphenyl-3-ol
-
; 0.001 mM, 10 min, 48% inhibition
4'-(6-methoxypyridin-3-yl)biphenyl-3-ol
-
0.001 mM, 10 min, 35% inhibition; 0.001 mM, 10 min, 58% inhibition
4'-cyanophenyl 3,4-methylenedioxycinnamate
-
-
4'-hydroxy-N-(3-hydroxybenzyl)-N-methylbiphenyl-3-carboxamide
4'-methoxy-N-(3-methoxybenzyl)-N-methylbiphenyl-3-carboxamide
-
;
4'-methoxy-N-(3-methoxyphenyl)-N-methyl-[1,1'-biphenyl]-4-sulfonamide
-
; 13% inhibition at 0.001 mM
4'-methoxy-N-(3-methoxyphenyl)-N-methylbiphenyl-3-carboxamide
-
-
4-(17beta-hydroxy-3-methoxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
-
0.01 mM, 38% inhibition, substrate: estrone
4-(3'-ethyl-4'-hydroxy-3-methyl-biphenyl)-4-oxo-N-pyridin-3-ylethyl-butyramide
-
15% inhibition at 0.001 mM
4-(3'-ethyl-4'-hydroxy-3-methyl-biphenyl)-4-oxo-N-pyridin-3-ylmethyl-butyramide
-
21% inhibition at 0.001 mM; 37°C, 0.001 mM, 21% inhibition, substrate: estrone,7beta-HSD type 1
4-(3'-ethyl-4'-hydroxy-biphenyl)-2,2-dimethyl-4-oxo-N-pyridin-3-ylethyl-butyramide
-
15% inhibition at 0.001 mM; 37°C, 0.001 mM, 15% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3'-ethyl-4'-hydroxy-biphenyl)-2,2-dimethyl-4-oxo-N-pyridin-3-ylmethyl-butyramide
-
38% inhibition at 0.001 mM
4-(3'-ethyl-4'-hydroxy-biphenyl)-4-oxo-N-(2-hydroxyethyl)-butyramide
-
23% inhibition at 0.001 mM; 37°C, 0.001 mM, 23% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3'-ethyl-4'-hydroxy-biphenyl)-4-oxo-N-pyridin-3-ylethyl-butyramide
-
17% inhibition at 0.001 mM; 37°C, 0.001 mM, 17% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3'-ethyl-4'-hydroxy-biphenyl)-4-oxo-N-pyridin-3-ylmethyl-butyramide
-
24% inhibition at 0.001 mM; 37°C, 0.001 mM, 24% inhibition, substrate: estrone, 7beta-HSD type 1; 37°C, 0.01 mM, 12% inhibition, substrate: estradiol-17beta, 7beta-HSD type 2
4-(3'-ethyl-4'-methoxy-biphenyl)-2,2-dimethyl-4-oxo-N-pyridin-3-ylmethyl-butyramide
-
17% inhibition at 0.001 mM; 37°C, 0.001 mM, 17% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3,17beta-dihydroxy-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
-
0.01 mM, 74% inhibition, substrate: estrone
4-(3-ethyl-4-hydroxy-3-methyl-biphenyl)-4-oxo-N-pyridin-3-ylethyl-butyramide
-
37°C, 0.001 mM, 15% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3-ethyl-4-hydroxy-biphenyl)-2,2-dimethyl-4-oxo-N-pyridin-3-ylmethyl-butyramide
-
37°C, 0.001 mM, 38% inhibition, substrate: estrone, 7beta-HSD type 1
4-(3-Hydroxy-17-oxo-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
-
0.01 mM, 76% inhibition, substrate: estrone
4-(3-methoxy-17-oxo-estra-1,3,5(10)-trien-16beta-ylmethyl)-benzamide
-
0.01 mM, 56% inhibition, substrate: estrone
4-(octanoylamino)phenyl (2E)-3-phenylprop-2-enoate
-
15% inhibition at 0.006 mM
4-bromo-N-(3-fluorophenyl)benzenesulfonamide
-
-
4-chloro-N-(3-hydroxy-4-methylphenyl)benzenesulfonamide
-
45% inhibition at 0.02 mM
4-chloro-N-(3-hydroxyphenyl)-2,5-dimethylbenzenesulfonamide
-
-
4-chloro-N-(4-hydroxyphenyl)benzenesulfonamide
-
55% inhibition at 0.02 mM
4-chloro-N-(4-methoxyphenyl)benzenesulfonamide
-
-
4-chloro-N-[2-(hydroxymethyl)phenyl]benzenesulfonamide
-
-
4-cyanophenyl (2E)-3-(1,3-benzodioxol-5-yl)prop-2-enoate
-
76% inhibition at 0.006 mM
4-fluoro-3-hydroxy-N-(3'-hydroxybiphenyl-3-yl)-N-methylbenzenesulfonamide
-
80% inhibition at 0.001 mM; 96% inhibition at 0.001 mM
4-fluoro-3-methoxy-N-(3'-methoxybiphenyl-3-yl)-N-methylbenzenesulfonamide
-
; 17% inhibition at 0.001 mM
4-fluoro-N-[2-(1-hydroxyethyl)phenyl]benzenesulfonamide
-
-
4-hydroxychalcone
-
IC50: 0.016 mM
4-methyl-3-(trifluoromethyl)-5-[[4-(trifluoromethyl)benzyl]sulfanyl]-4H-1,2,4-triazole
-
-
4-methyl-5-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-4H-1,2,4-triazole-3-thiol
-
-
4-methyl-N-[4-[4-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]benzenesulfonamide
-
-
4-methylbenzylidene camphor
-
-
4-propanoylphenyl 3-(acetylamino)benzenesulfonate
-
67% inhibition at 0.02 mM
4-[(15beta)-3-hydroxy-17-oxo-2-propylestra-1(10),2,4-trien-15-yl]-N-[2-(7-methyl-1H-indol-2-yl)ethyl]butanamide
-
0.0001 mM, 69% inhibition
4-[(15beta)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-[2-(7-methyl-1H-indol-3-yl)ethyl]butanamide
-
-
4-[5-(3-hydroxyphenyl)thiophen-2-yl]-2-methylphenol
-
-
4-[[(4-methoxy-2,5-dimethylphenyl)sulfonyl]amino]benzoic acid
-
-
5'-ADP
-
-
5'-ADP-ribose
-
-
5'-AMP
-
-
5'-ATP
-
-
5'-O-(10-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-decanoyl)adenosine
-
IC50: 140 nM
5'-O-(11-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-undecanoyl) adenosine
-
IC50: 310 nM
5'-O-(11-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha/beta-yl]-undecanoyl)adenosine
-
IC50: 90 nM
5'-O-(11-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'beta-yl]-undecanoyl)adenosine
-
IC50: 120 nM
5'-O-(12-[3',17'beta-(dihydroxy)-1',3',5'(10')-estratrien-16'alpha-yl]-dodecanoyl)adenosine
-
IC50: 1000 nM
5'-O-(6-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha/beta-yl]-hexanoyl)adenosine
-
IC50: 6900 nM
5'-O-(7-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-heptanoyl)adenosine
-
IC50: 430 nM
5'-O-(8-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-octanoyl)adenosine
-
IC50: 93 nM
5'-O-(9-[3',17'beta-dihydroxy-1',3',5'(10')-estratrien-16'alpha-yl]-nonanoyl)adenosine
-
IC50: 52 nM
5'-O-[9-[(16b,17b)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]nonanoyl]adenosine
-
-
5'-O-[9-[(16beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]nonanoyl]adenosine
-
EM-1745, bisubstrate inhibitor of 17beta-HSD1
5,7-dihydroxy-4'-methoxy-flavone
-
-
5-(2-fluoro-3-methoxyphenyl)-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide
-
-
5-(2-fluoro-3-methoxyphenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
-
-
5-(2-fluoro-3-methoxyphenyl)-N-methyl-N-(3-methylphenyl)thiophene-2-carboxamide
-
-
5-(2-hydroxyphenyl)-N-(3-hydroxyphenyl)-N-methylthiophene-2-carboxamide
-
-
5-(2-methoxyphenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
-
-
5-(3-ethyl-4-hydroxyphenyl)-indan-1-one
-
37°C, 0.01 mM, 48% inhibition, substrate: estradiol-17beta, 7beta-HSD type 2; 37°C, 0.01 mM, 86% inhibition, substrate: estrone, 7beta-HSD type 1; 86% inhibition at 0.001 mM
5-(3-fluoro-4-hydroxyphenyl)-indan-1-one
-
37°C, 0.01 mM, 24% inhibition, substrate: estradiol-17beta, 7beta-HSD type 2; 37°C, 0.01 mM, 75% inhibition, substrate: estrone, 7beta-HSD type 1; 75% inhibition at 0.001 mM
5-(3-fluoro-4-methoxyphenyl)-indan-1-one
-
37°C, 0.01 mM, 56% inhibition, substrate: estrone, 7beta-HSD type 1; 56% inhibition at 0.001 mM
5-(3-fluorophenyl)-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide
-
-
5-(3-fluorophenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
-
-
5-(4-cyanophenyl)-N-(3-hydroxybenzyl)-N-methylthiophene-2-carboxamide
-
-
5-(4-cyanophenyl)-N-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
-
; 48% inhibition
5-(4-hydroxyphenyl)-indan-1-one
-
37°C, 0.01 mM, 17% inhibition, substrate: estradiol-17beta, 7beta-HSD type 2; 37°C, 0.01 mM, 81% inhibition, substrate: estrone, 7beta-HSD type 1; 81% inhibition at 0.001 mM
5-(6-hydroxy-2-naphthyl)pyridin-3-ol
-
0.001 mM, 58% inhibition, substrate: estrone
5-androsten-3beta-ol
-
-
5-androstene-3beta,16beta-diol
-
-
5-benzyl-3-(furan-2-ylmethyl)-8-hydroxy-2-(2-phenylethyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
5% inhibition at 100 nM, 26% inhibition at 0.001 mM
5-bromo-3-(2-methylpropyl)-2-(3,4,5-trimethoxyphenyl)-6,7-dihydro[1]benzothieno[2,3-d]pyrimidine-4,8(3H,5H)-dione
-
0.001 mM, 54% inhibition
5-butyl-3-(furan-2-ylmethyl)-8-hydroxy-2-(2-phenylethyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
9% inhibition at 100 nM, 27% inhibition at 0.001 mM
5-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-(2-thiophen-2-ylethyl)pentanamide
-
-
6-(3-ethyl-4-hydroxyphenyl)-3,4-dihydro-2H-naphthalen-1-one
-
37°C, 0.01 mM, 51% inhibition, substrate: estrone, 7beta-HSD type 1; 51% inhibition at 0.001 mM
6-(3-ethyl-4-methoxyphenyl)-3,4-dihydro-2H-naphthalen-1-one
-
37°C, 0.01 mM, 71% inhibition, substrate: estrone, 7beta-HSD type 1; 71% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-((4-methylphenyl)sulfonyl)-2-naphthol
-
75% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-(morpholin-4-ylcarbonyl)-2-naphthol
-
62% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-(phenylsulfonyl)-2-naphthol
-
33% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-(piperazin-1-ylcarbonyl)-2-naphthol
-
45% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-(piperidin-1-ylcarbonyl)-2-naphthol
-
73% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-1-naphthol
-
0.001 mM, 23% inhibition, substrate: estrone
6-(3-hydroxyphenyl)-1-phenyl-2-naphthol
-
89% inhibition at 0.001 mM
6-(3-hydroxyphenyl)-2-naphthol
6-(3-hydroxyphenyl)-3,4-dihydronaphthalen-1(2H)-one
-
0.001 mM, 23% inhibition, substrate: estrone
6-(4-hydroxy-phenyl)-3,4-dihydro-2H-naphthalen-1-one
-
37°C, 0.01 mM, 89% inhibition, substrate: estrone, 7beta-HSD type 1; 89% inhibition at 0.001 mM
6-(4-hydroxyphenyl)-1-naphthol
-
0.001 mM, 55% inhibition, substrate: estrone
6-(4-hydroxyphenyl)naphthalen-1-ol
-
-
6-(hexylsulfanyl)estra-1(10),2,4-triene-3,17beta-diol
-
30% inhibition at 0.001 mM, reduction of estrone with NADH as cofactor
6-butyl-3-(furan-2-ylmethyl)-8-hydroxy-2-(2-phenylethyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
52% inhibition at 100 nM, 81% inhibition at 0.001 mM
6-hydroxyflavone
-
53.3% inhibition at 0.006 mM
6-pyridin-3-yl-2-naphthol
-
0.001 mM, 32% inhibition, substrate: estrone
6-[(1,3-benzothiazol-2-ylsulfanyl)methyl]-4-butoxy-2-(trifluoromethyl)quinoline
-
-
6-[4-(hydroxymethyl)phenyl]-2-naphthol
-
0.001 mM, 13% inhibition, substrate: estrone
6-[4-(trifluoromethyl)phenoxy]pyridin-3-amine
-
-
7,4'-Dihydroxyflavone
-
more than 90% inhibition at 0.006 mM
7-(3-hydroxyphenyl)-2-naphthol
-
0.001 mM, 62% inhibition, substrate: estrone
7-hydroxy-3-(3-hydroxyphenyl)-1-naphthonitrile
-
53% inhibition at 0.001 mM
7-hydroxy-flavanone
-
IC50: 0.028 mM
7-hydroxy-flavone
-
IC50: 0.0009 mM
8-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-octanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester
-
IC50: 93 nM
8-hydroxy-3-(2-methylbutyl)-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
91% inhibition at 100 nM, 94% inhibition at 0.001 mM
8-hydroxy-3-(2-methylprop-1-en-1-yl)-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
0.001 mM, 97% inhibition
8-hydroxy-3-(2-methylpropyl)-2-(3,4,5-trimethoxyphenyl)[1]benzothieno[2,3-d]pyrimidin-4(3H)-one
-
93% inhibition at 100 nM, 98% inhibition at 0.001 mM
9-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-nonanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester
-
IC50: 52 nM
9-(5-O-(9-[(16alpha,17alpha)-3,17-dihydroxyestra-1(10),2,4-trien-16-yl]nonanoyl)-alpha-L-arabinofuranosyl)-9H-purin-6-amine
-
shows key interactions with two different enzyme-binding sites, namely the substrate- and the cofactor-binding sites
arachidonic acid
-
0.018 mM, complete inhibition, oxidation of estradiol
baicalein
-
i.e. 5,6,7-trihydroxyflavone, 61% inhibition at 0.006 mM
Benzoic acid (13S,17R)-7-[10-(butyl-methyl-carbamoyl)-decyl]-17-ethynyl-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl ester
-
-
benzyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate
-
60% inhibition at 0.006 mM
benzyl (2E)-3-phenylprop-2-enoate
-
35% inhibition at 0.006 mM
benzyl alcohol
-
-
caffeic acid
-
18% inhibition at 0.05 mM
CC-156
-
potent inhibitor
chrysoeriol
-
i.e. 4',5,7-trihydroxy-3'-methoxyflavone, 82% inhibition at 0.006 mM
Cinnamic acid
coumarin-3-carboxylic acid
coumestrol
-
IC50: 0.0002 mM
Cu2+
-
1 mM, 82% inhibition
Cyclohexanol
-
-
cyclohexyl (2E)-3-phenylprop-2-enoate
-
25% inhibition at 0.006 mM
Cyclopentanol
-
-
D-secoalcohol estrone
-
-
-
D-secooxime
-
-
diethylstilbestrol
diosmetin
-
i.e. 3',5,7-trihydroxy-4'-methoxyflavone, more than 90% inhibition at 0.006 mM
Disulfiram
-
irreversible inhibition
Dithiocarbamate
-
irreversible inhibition of 17beta-HSD1, preincubation with NADPH protects from inhibition
EM-139
EM-1745
enterodiol
-
-
enterolactone
-
0.05 mM, 84% inhibition
equilin
estrone
ethyl (2Z)-hydroxy[(16Z)-3-hydroxy-17-oxoestra-1(10),2,4-trien-16-ylidene]ethanoate
-
-
ethyl 4-[([4-[(15alpha)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]butyl]carbamoyl)amino]benzoate
-
-
ethyl [(6aS)-2-hydroxy-6a-methyl-4b,5,6,6a,8,10,10a,10b,11,12-decahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-9-yl]acetate
-
-
eupatorin
-
37% inhibition at 0.006 mM
fisetin
-
72% inhibition at 0.006 mM
genistein
-
0.05 mM, 59% inhibition
genkwanin
-
3',5-dihydroxy-7-methoxyflavone, 81% inhibition at 0.006 mM
Glyoxal
-
40 mM, pH 8.5, t1/2: 29 h
gossypol
-
and derivatives of gossypol, competitive with respect to NAD+ in reverse reaction
iodoacetamide
-
1 mM, 78% inhibition
linoleic acid
-
0.018 mM, 58% inhibition, oxidation of estradiol
linolenic acid
-
0.018 mM, 34% inhibition, oxidation of estradiol
m-coumaric acid
-
-
maneb
-
irreversible inhibition
medrogestone
-
although the inhibitor is not selective for the type 1 17beta-HSD, it is weakly active and has a mechanism that appears to be complex, it offers new possibilities in treatment of estrogen-dependent diseases
methyl 3-hydroxy-17-oxoestra-1(10),2,4-triene-16-carboxylate
-
0.01 mM, 69% inhibition
methyl [(6aS)-2-hydroxy-6a-methyl-4b,6,6a,10,10a,10b,11,12-octahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-8(5H)-yl]acetate
-
-
Mg2+
-
1 mM, 18% inhibition
myricetin
-
i.e. 3,3',4',5',5,7-hexahydroxyflavone, 52% inhibition at 0.006 mM
N'-[(2,4-difluorophenyl)sulfonyl]-2-pyridin-3-yl-4,5-dihydro-1,3-thiazole-4-carbohydrazide
-
-
N,4'-dimethyl-N-(3-methylphenyl)biphenyl-4-carboxamide
-
-
N,5-bis(3-hydroxyphenyl)-N-methylthiophene-2-carboxamide
-
33% inhibition
N,5-bis(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
-
-
N-(1,3-benzodioxol-5-ylmethyl)-5-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]pentanamide
-
-
N-(2,1,3-benzothiadiazol-4-yl)-2-(pyrimidin-2-ylsulfanyl)acetamide
-
-
N-(2,1,3-benzothiadiazol-4-yl)-2-[(4-hydroxypyrimidin-2-yl)sulfanyl]acetamide
-
92% inhibition at 0.02 mM
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-methyl-1,2,3-thiadiazole-5-carboxamide
-
-
N-(2,4-difluorobenzyl)-4-[(15beta)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]butanamide
-
-
N-(2,5-dimethoxyphenyl)-2,5-diethylbenzenesulfonamide
-
-
N-(2-hydroxyphenyl)-2-methyl-4-(trifluoromethyl)benzenesulfonamide
-
94% inhibition at 0.02 mM
N-(2-[[(2,3,5,6-tetramethylphenyl)sulfonyl]amino]phenyl)acetamide
-
-
N-(3-chloro-4-fluorophenyl)-4-fluorobenzenesulfonamide
-
45% inhibition at 0.02 mM
N-(3-chloro-4-hydroxyphenyl)-4-fluorobenzenesulfonamide
-
91% inhibition at 0.02 mM
N-(3-chlorophenyl)-4-fluorobenzenesulfonamide
-
-
N-(3-hydroxy-4-methylphenyl)-3-(trifluoromethyl)benzenesulfonamide
-
75% inhibition at 0.02 mM
N-(3-hydroxy-4-methylphenyl)-4-methoxybenzenesulfonamide
-
47% inhibition at 0.02 mM
N-(3-hydroxybenzyl)-5-(3-hydroxyphenyl)-N-methylthiophene-2-carboxamide
-
-
N-(3-hydroxybenzyl)-5-(4-hydroxyphenyl)-N-methylthiophene-2-carboxamide
-
-
N-(3-hydroxybenzyl)-5-(4-methoxyphenyl)-N-methylthiophene-2-carboxamide
-
-
N-(3-hydroxybenzyl)-N-methyl-5-(3-methylphenyl)thiophene-2-carboxamide
-
-
N-(3-hydroxyphenyl)-2,4,5-trimethylbenzenesulfonamide
-
47% inhibition at 0.02 mM
N-(3-hydroxyphenyl)-3'-methoxy-N-methyl-[1,1'-biphenyl]-4-sulfonamide
-
; 18% inhibition at 0.001 mM
N-(3-hydroxyphenyl)-4-methoxy-2,5-dimethylbenzenesulfonamide
-
85% inhibition at 0.02 mM
N-(3-hydroxyphenyl)-4-methoxy-2-methyl-5,6,7,8-tetrahydronaphthalene-1-sulfonamide
-
-
N-(3-hydroxyphenyl)-N,3'-dimethyl-[1,1'-biphenyl]-4-sulfonamide
-
15% inhibition at 0.001 mM; 22% inhibition at 0.001 mM
N-(3-hydroxyphenyl)-N-methyl-4-(thiophen-2-yl)benzenesulfonamide
-
; 31% inhibition at 0.001 mM
N-(3-hydroxyphenyl)benzenesulfonamide
-
-
N-(3-methoxybenzyl)-5-(3-methoxyphenyl)-N-methylthiophene-2-carboxamide
-
-
N-(3-methoxyphenyl)-N-methyl-4-(thiophen-2-yl)benzenesulfonamide
-
; 32% inhibition at 0.001 mM
N-(3-methoxyphenyl)-N-methyl-4-(thiophen-3-yl)benzenesulfonamide
-
; 23% inhibition at 0.001 mM
N-(3-methoxyphenyl)-N-methyl-5-(3-methylphenyl)thiophene-2-carboxamide
-
-
N-(4-chlorophenyl)-4-methoxy-2,5-dimethylbenzenesulfonamide
-
-
N-(4-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-4-methoxybenzenesulfonamide
-
-
N-(4-hydroxyphenyl)-2,4,6-trimethylbenzenesulfonamide
-
33% inhibition at 0.02 mM
N-(4-hydroxyphenyl)-2,5-dimethylbenzenesulfonamide
-
39% inhibition at 0.02 mM
N-(4-hydroxyphenyl)-N-methyl-4-(pyridin-3-yl)benzenesulfonamide
-
14% inhibition at 0.001 mM; 15% inhibition at 0.001 mM
N-(4-methoxyphenyl)-2,5-dimethylbenzenesulfonamide
-
-
N-(5-chloro-2-hydroxyphenyl)-4-fluoro-3-methylbenzenesulfonamide
-
44% inhibition at 0.02 mM
N-(5-chloro-2-methylphenyl)-4-fluorobenzenesulfonamide
-
-
N-benzyl-4-[(15alpha)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]butanamide
-
-
N-benzyl-4-[(15beta)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]butanamide
-
-
N-benzyl-4-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-methylbutanamide
-
-
N-butyl-6-[[(6beta,17beta)-17-hydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]oxy]-N-methylhexanamide
N-butyl-6-[[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]sulfanyl]-N-methylhexanamide
N-butyl-7-[(6beta,17beta)-3,17-dihydroxyestra-1(10),2,4-trien-6-yl]-N-methylheptanamide
-
-
N-butyl-N-methyl-11-[16beta-(3-carbamoylbenzyl)-3,17-dihydroxy-estra-1,3,5(10)-trien-7alpha-yl]-undecanamide
-
0.01 mM, 61% inhibition, substrate: estrone
N-cyclohexyl-3-[(15beta)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]propanimidamide
-
-
N-cyclohexyl-3-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]-N-methylpropanamide
-
-
N-cyclohexyl-3-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]propanamide
-
-
N-cyclooctyl-3-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]propanamide
-
-
N-ethylmaleimide
-
irreversible inhibition; irreversible inhibition of 17beta-HSD1, preincubation with NADPH protects from inhibition
N-methyl-N,5-bis(3-methylphenyl)thiophene-2-carboxamide
-
-
N-n-butyl-N-methyl-11-(16'a-bromo-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-butyl-N-methyl-11-(16'a-chloro-3',17'a-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-butyl-N-methyl-11-(16'a-chloro-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-butyl-N-methyl-11-(16'a-fluoro-3',17'a-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-butyl-N-methyl-11-(16'a-fluoro-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-butyl-N-methyl-11-(16'a-iodo-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide
-
-
N-n-Butyl-N-methyl-11-(3,17b-dihydroxyestra-1,3,5(10)-trien-7a-yl)undecanamide
-
-
N-[2-(4-hydroxyphenyl)ethyl]-3-[(15beta)-3-methoxy-17-oxoestra-1(10),2,4-trien-15-yl]propanamide
-
-
N-[3-(6-hydroxy-2-naphthyl)phenyl]acetamide
-
0.001 mM, 19% inhibition, substrate: estrone
N-[[(15alpha)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]methyl]-N-methylthiophene-2-sulfonamide
-
-
N-[[(15alpha)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]methyl]benzenesulfonamide
-
-
N-[[(15alpha)-3-hydroxy-17-oxoestra-1(10),2,4-trien-15-yl]methyl]thiophene-2-sulfonamide
-
-
N-[[5-(2,5-dichlorophenyl)furan-2-yl]methyl]-2H-tetrazol-5-amine
-
71% inhibition at 0.02 mM
NADP+
-
strong inhibitor of NAD+-linked activity
naphthalen-2-yl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate
-
56% inhibition at 0.006 mM
nomegestrol acetate
-
although the inhibitor is not selective for the type 1 17beta-HSD, it is weakly active and has a mechanism that appears to be complex, it offers new possibilities in treatment of estrogen-dependent diseases
oleic acid
-
0.018 mM, complete inhibition, oxidation of estradiol
p-aminocinnamic acid
-
-
p-carboxycinnamic acid
-
-
p-nitro-cinnamic acid
-
-
palm oil carotenoids
-
0.0001 mM, significant inhibition of the conversion of estradiol to estrone in the MCF-7 cell line
-
PCMB
-
1 mM, complete inhibition
phenol
-
noncompetitive
phenyl (2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate
-
35% inhibition at 0.006 mM
Phenylglyoxal
-
40 mM, pH 8.5, t1/2: 0.33 h
S-(4-fluorophenyl) 2-methyl-4-(trifluoromethyl)benzenecarbothioate
-
-
S-[(7R,10R,13S,17R)-10,13-dimethyl-3,5'-dioxo-1,2,3,4',5',6,7,8,9,10,11,12,13,14,15,16-hexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-17,2'-furan]-7-yl] ethanethioate
-
0.003 mM, 57% inhibition, substrate: 4-androstene-3,17-dione
scutellarein
-
i.e. 4',5,6,7-tetrahydroxyflavone, 88% inhibition at 0.006 mM
STX1040
-
-
testosterone
-
weak
thiram
-
irreversible inhibition
tibolone
-
although the inhibitor is not selective for the type 1 17beta-HSD, it is weakly active and has a mechanism that appears to be complex, it offers new possibilities in treatment of estrogen-dependent diseases
vitamin D3
-
inhibits reductive activity in HCT8 and LoVo cells
zineb
-
irreversible inhibition
Zn2+
-
1 mM, 33% inhibition
[4-[4-(2-methoxyphenyl)piperidin-1-yl]-3-nitrophenyl]methanol
-
-
[6-(3,4-dihydroxyphenyl)pyridin-2-yl]-(4-fluoro-3-hydroxyphenyl)methanone
-
a potent nonsteroidal inhibitor, binding structure, overview
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
palm oil carotenoids
-
0.001 mM, significant stimulation of the conversion of estradiol to estrone in the MCF-7 cell line
-
R5020
-
stimulates conversion of estradiol to estrone in T47D cells in culture
retinoic acid
-
0.001 mM, significant stimulation of the conversion of estradiol to estrone in the MCF-7 cell line and MDA-MB-231 cell line, 0.0001 mM has no effect
vitamin D3
-
activates oxidative activity in HCT8 and LoVo cells